Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
NCT00826371
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
114
Enrollment
INDUSTRY
Sponsor class
Conditions
Age Related Macular Degeneration
Interventions
DRUG:
ranibizumab 0.5 mg
Sponsor
Novartis Pharmaceuticals